Ascendis Pharma AS (FRA:A71) Cyclically Adjusted Book per Share: €6.91 (As of Mar. 2026)


FRA:A71 Ascendis Pharma AS FRA:A71
37 GF Score
Price €206.00
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted Book per Share?

Ascendis Pharma AS FRA:A71 +0.98% 37 Cyclically Adjusted Book per Share is €6.91 as of Mar. 2026. GuruFocus rates FRA:A71 with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ascendis Pharma AS's adjusted book value per share for the three months ended in Mar. 2026 was €7.948. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.91 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ascendis Pharma AS's average Cyclically Adjusted Book Growth Rate was -6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-08), Ascendis Pharma AS's current stock price is €206.00. Ascendis Pharma AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €6.91. Ascendis Pharma AS's Cyclically Adjusted PB Ratio of today is 29.81.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ascendis Pharma AS was 32.52. The lowest was 24.93. And the median was 27.82.


Ascendis Pharma AS  (FRA:A71) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ascendis Pharma AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=206.00/6.91
=29.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ascendis Pharma AS was 32.52. The lowest was 24.93. And the median was 27.82.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ascendis Pharma AS Cyclically Adjusted Book per Share Related Terms


Ascendis Pharma AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted Book per Share Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 9.11 8.82 6.90

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.15 7.42 7.25 6.90 6.91

FRA:A71 vs JAZZ, BBIO, EXEL: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PB Ratio falls into.


FRA:A71
37GF Score
Ascendis Pharma AS FRA:A71
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma AS's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=7.948/121.6800*121.6800
=7.948

Current CPI (Mar. 2026) = 121.6800.

Ascendis Pharma AS Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.618 100.600 4.376
201609 2.951 100.200 3.584
201612 5.447 100.300 6.608
201703 4.763 101.200 5.727
201706 3.891 101.200 4.678
201709 5.559 101.800 6.645
201712 5.062 101.300 6.080
201803 8.367 101.700 10.011
201806 7.940 102.300 9.444
201809 7.237 102.400 8.600
201812 6.646 102.100 7.921
201903 15.272 102.900 18.059
201906 14.199 102.900 16.790
201909 13.844 102.900 16.371
201912 12.444 102.900 14.715
202003 11.437 103.300 13.472
202006 9.869 103.200 11.636
202009 17.815 103.500 20.944
202012 15.604 103.400 18.363
202103 14.914 104.300 17.399
202106 12.755 105.000 14.781
202109 17.468 105.800 20.090
202112 15.562 106.600 17.763
202203 12.057 109.900 13.349
202206 10.891 113.600 11.666
202209 7.918 116.400 8.277
202212 4.608 115.900 4.838
202303 2.974 117.300 3.085
202306 1.147 116.400 1.199
202309 -1.299 117.400 -1.346
202312 -2.574 116.700 -2.684
202403 -4.169 118.400 -4.284
202406 -5.600 118.500 -5.750
202409 -1.629 118.900 -1.667
202412 -1.766 118.900 -1.807
202503 -3.144 120.200 -3.183
202506 -3.098 120.700 -3.123
202509 -2.849 121.600 -2.851
202512 -2.653 121.200 -2.664
202603 7.948 121.680 7.948

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €6.91 mean?
Ascendis Pharma AS (FRA:A71) has a Cyclically Adjusted Book per Share of €6.91 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Cyclically Adjusted Book per Share too high?
Ascendis Pharma AS's current Cyclically Adjusted Book per Share is €6.91. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Cyclically Adjusted Book per Share compare to JAZZ and BBIO?
Ascendis Pharma AS's Cyclically Adjusted Book per Share of €6.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Cyclically Adjusted Book per Share is €6.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (FRA:A71) has a current Cyclically Adjusted Book per Share of €6.91. The current Cyclically Adjusted Book per Share is €6.91. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ascendis Pharma AS (FRA:A71), the current Cyclically Adjusted Book per Share is €6.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for FRA:A71

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€206.00
Price